COVID-19: Pfizer vaccine protection drops to 47% after six months


The effectiveness of the Pfizer-BioNTech vaccine against infection by COVID-19 falls to 47% six months after the second vaccine dose, a new study shows.

The peer-review analysis, which was published in the Lancet medical journal, found that two doses of the vaccine were 90% effective against COVID-19 hospitalisation for at least six months, but only 47% effective against infection after that period.

Researchers analysed the electronic health records of 3.4 million people who had received the Pfizer-BioNTech vaccines.

The reduction in the vaccine’s effectiveness against COVID-19 infection was due to its waning over time and not because of Delta or other variants, the study found.

“Our variant-specific analysis clearly shows that the BNT162b2 vaccine is effective against all current variants of concern, including Delta,” said Dr Luis Jodar, chief medical officer at Pfizer Vaccines.

“COVID-19 infections in people who have received two vaccine doses are most likely due to waning and not caused by Delta or other variants escaping vaccine protection.”


Please enter your comment!
Please enter your name here